Addiction Medicine: Beyond the Abstract

In today's Episode Rewind we're revisiting our interview with Dr. Marcela Smid, live at the 56th Annual ASAM Conference in Denver. Dr. Smid sits down to discuss article submissions and peer review, as well as demystifying the scientific publishing process for new authors.

 

Learn more about this year's upcoming conference in San Diego, CA > https://bit.ly/3OTOx79

In this episode of Beyond The Abstract, Dr. Matthew Sloan sits down to discuss findings from his recent article Symptom-Triggered Alcohol Withdrawal Management Delivered Over Telemedicine featured in the November/December issue of the Journal of Addiction Medicine. Join us as Dr. Sloan shares insights into his study investigating the feasibility of delivering symptom-triggered alcohol withdrawal management over telemedicine.

 

Dr. Matthew Sloan is a clinician scientist at the Centre for Addiction and Mental Health in Toronto, Ontario, Canada. He specializes in the treatment of substance use disorders and their psychiatric comorbidities. He completed medical school and psychiatry residency at McGill University followed by a postdoctoral fellowship in human psychopharmacology at the National Institutes of Health and an addiction psychiatry fellowship at Yale University. Dr. Sloan's primary research interests are developing innovative new treatments for substance use disorders and exploring determinants of psychopharmacological response to drugs of misuse. He has obtained competitive research funding from the Canadian Institutes of Health Research, Health Canada, and the Centre for Addiction and Mental Health Discovery Fund and has received scientific prizes from the American Academy of Addiction Psychiatry and the National Institute on Alcohol Abuse and Alcoholism.

 

Article Link: Symptom-Triggered Alcohol Withdrawal Management Delivered Over Telemedicine

In this episode, Dr. Nicolas Garel joins the podcast to discuss findings from his new article in the September/October issue of the Journal of Addiction Medicine titled Increased Risks of Major Cardiac Adverse Events in Stimulant Use Disorder as Compared With Other Substance Use Disorders: A Propensity-score Matching Cohort Study.

Dr. Nicolas Garel is a psychiatrist and clinician-scientist at the Centre Hospitalier de l’Université de Montréal (CHUM). He is an assistant professor in the Department of Psychiatry at the Université de Montréal and adjunct professor in the Department of Psychiatry and Behavioral Sciences at Stanford University. Dr. Garel completed his medical degree at the Université de Montréal, followed by his psychiatry residency and clinician-scientist fellowship at McGill University, and later pursued advanced training in research and addiction medicine at Stanford University. His research program focuses on innovative interventions for treatment-resistant mood disorders and substance use disorders.

 

Article Link: Increased Risks of Major Cardiac Adverse Events in Stimulant Use Disorder as Compared With Other Substance Use Disorders: A Propensity-score Matching Cohort Study

In this episode, Dr. Blythe Bynum joins the show to discuss her new article titled Navigating Choices: Pregnancy Options Counseling Experiences in Individuals With Opioid Use Disorder, featured in the November/December issue of the Journal of Addiction Medicine.

Dr. Blythe Bynum is an assistant professor in the Department of Obstetrics and Gynecology at Thomas Jefferson University in Philadelphia, Pennsylvania. She is a board certified OBGYN with fellowship training in Complex Family Planning. 

 

Article Link: Navigating Choices: Pregnancy Options Counseling Experiences in Individuals With Opioid Use Disorder

In this episode, Dr. Bradley Stein joins the show to discuss findings from his new study titled Medicaid Unwinding: Association With New and Ending Buprenorphine Treatment Episodes, featured in the September/October issue of the Journal of Addiction Medicine.

Dr. Bradley Stein is a practicing physician and senior physician policy researcher at RAND. His research career has focused on improving access to, quality of, and outcomes from care of individuals with mental health and substance use disorders being treated in community settings. For two decades, Dr. Stein has studied the opioid crisis, serving as principal investigator for numerous federally and privately funded studies. He has published multiple peer-reviewed articles related to studies of opioid use disorder treatment, harm reduction, and the effects of state and federal policies, and he has provided Congressional testimony related to his research on multiple occasions. And his work has been covered by a range of media outlets including the Economist, Washington Post, and New York Times.

 

Article Link: Medicaid Unwinding: Association With New and Ending Buprenorphine Treatment Episodes

Guest Editorial: Medicaid Unwinding May Have Substantially Disrupted Buprenorphine Treatment